# Boltz raises $110M led by Bessemer to sell AI drug design models

> The MIT spinout behind the open-source Boltz-2 model says paid usage grew 50-fold since June, with Pfizer, GSK, Takeda and BMS as partners.

URL: https://claudegpt.si/news/boltz-series-a-110m  
Published: 2026-11-19T10:58:23.987Z  
Author: ClaudeGPT Si Newsroom  
Section: AI News  
Topics: Boltz, Funding, Drug discovery, Startups  
Publisher: ClaudeGPT Si

## Key takeaways

- Boltz raised a $110 million Series A led by Bessemer Venture Partners on November 18, 2026.
- It sells its paid BoltzMol-1 and BoltzProt-1 models through Boltz Lab and an API, alongside open-source models like Boltz-2.
- Boltz says paid usage grew 50-fold since June and names Pfizer, GSK, Takeda and BMS as partners.

Boltz, a startup that builds AI models for designing drug molecules, [raised a $110 million Series A](https://boltz.com/series-a) on November 18, 2026. Bessemer Venture Partners led the round, and Bessemer's Andrew Hedin and Byron Deeter join the company. Earlier backers Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures put in more, and Greycroft, F-Prime Capital, Hummingbird and Benchling joined.

Boltz started in 2025 as a group of MIT researchers and is best known for open-source models that predict how molecules interact. Its open models include Boltz-2 and BoltzGen. In June 2026 it released its first paid models, BoltzMol-1 and BoltzProt-1, which it sells through Boltz Lab, a design platform launched in January, and through an API that AI agents can call. [Andreessen Horowitz says](https://a16z.com/announcement/investing-in-boltz/) the API works with coding agents such as Claude Code and Codex.

The numbers Boltz gives are about usage, not revenue. It charges per "molecular token", and says paying customers used 50 times as many of them in early November as they did in mid-June. It counts six of the 20 largest drug companies as partners, naming Pfizer, GSK, Takeda and BMS. It has about 40 scientists and engineers.

The round is a bet that drug design will be sold the way language models are: open models to win researchers, then paid models and metered API calls for companies. Boltz says the money goes to compute, data and hiring. Biology AI drew large checks this week: [Isomorphic Labs raised $5 billion](https://claudegpt.si/news/isomorphic-labs-series-c-5-billion) on November 17.

## Sources

- [Announcing our Series A](https://boltz.com/series-a), Boltz
- [Investing in Boltz](https://a16z.com/announcement/investing-in-boltz/), Andreessen Horowitz
